Journal article

Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial

Elizabeth J Hovey, Kathryn M Field, Mark A Rosenthal, Elizabeth H Barnes, Lawrence Cher, Anna K Nowak, Helen Wheeler, Kate Sawkins, Ann Livingstone, Pramit Phal, Christine Goh, John Simes

NEURO-ONCOLOGY PRACTICE | OXFORD UNIV PRESS | Published : 2017

Abstract

Background: In patients with recurrent glioblastoma, the benefit of bevacizumab beyond progression remains uncertain. We prospectively evaluated continuing or ceasing bevacizumab in patients who progressed while on bevacizumab. Methods: CABARET, a phase II study, initially randomized patients to bevacizumab with or without carboplatin (Part 1). At progression, eligible patients underwent a second randomization to continue or cease bevacizumab (Part 2). They could also receive additional chemotherapy regimens (carboplatin, temozolomide, or etoposide) or supportive care. Results: Of 120 patients treated in Part 1, 48 (80% of the anticipated 60-patient sample size) continued to Part 2. Despite ..

View full abstract

Grants

Awarded by NHMRC Program


Funding Acknowledgements

This study was funded by Roche Products, Pty Limited (Australia) with additional support from NHMRC Program Grant 1037786 to the NHMRC Clinical Trials Centre, and Cancer Australia Support for Cancer Clinical Trials Grant and CINSW Cooperative Clinical Trials Grant to COGNO.Dr. Field was funded through the University of Melbourne Stella Mary Langford Scholarship, Watt-Geyer Memorial Research Fund, and the Royal Melbourne Hospital Research Medal